Duluth, U.S. & Copenhagen, Denmark – March 30, 2017 – Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. The parties will focus on developing products for hatcheries, the facilities where eggs are hatched before the chickens move to grow-out farms. As part of the agreement, Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product for the U.S. poultry industry. Boehringer Ingelheim plans on expanding to other markets globally in the coming years.
“Boehringer Ingelheim is continuously exploring new science, products and industry categories, to deliver a powerful range of innovative solutions with a focus on customer needs. Poultry producers are looking for improved ways to deliver on the growing global need for sustainable protein,” said George Heidgerken, Global Head of Livestock at Boehringer Ingelheim. “Collaborating with Novozymes enables Boehringer Ingelheim to enter an exciting new segment of products to provide alternatives in an environment that is increasingly challenged by antibiotic bans.”
Probiotics are naturally occurring, live microbes that can improve the gut flora of poultry and other animals. Robust gut flora can significantly improve animal health, thereby providing a natural alternative to antibiotic growth promoters. Rising global consumption of meat, and legislative and consumer-driven curbs on the use of antibiotics as growth promoters in animal farming have increased demand for alternatives such as probiotics.
“We are excited to collaborate with Boehringer Ingelheim to develop a range of probiotic solutions for poultry that will improve sustainability in the industry”, said Susanne Palsten Buchardt, Vice President, Animal Health & Nutrition at Novozymes. “The collaboration is an important step in solidifying Novozymes’ capabilities within probiotics and helping poultry producers deliver greater quantities of safe, affordable protein. Utilizing Boehringer Ingelheim’s close relationships with large-scale producers, Novozymes will gain valuable access to new distribution channels and customers, many of which are seeking sustainable alternatives to antibiotic growth promoters”.
About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and aglobal presence in 99 countries.Formore information aboutBoehringerIngelheim Animal Health, click here.
About Boehringer Ingelheim
Boehringer Ingelheimisone of the world’s 20 leading pharmaceutical companies.Headquartered in Ingelheim,Germany, BoehringerIngelheim operates presently with a total ofsome 50,000 employees worldwide.The focusof the family-owned company,founded in 1885,is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, BoehringerIngelheim achieved net sales of about 14.8billioneuros. R&D expenditure correspondsto 20.3 per cent of netsales. Formore information, please visit www.boehringer-ingelheim.com.
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community,we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing,energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.
Media contact Boehringer Ingelheim
Heidi De Wit-Sommerfeld
+1 678 638 3763
Media contac tNovozymes
+1 646 671 3897